Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.55 USD
Change Today +0.02 / 0.44%
Volume 33.5K
MSLP On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

muscle pharm corp (MSLP) Key Developments

MusclePharm Corporation Reaches Agreement in Principle in SEC Investigation

MusclePharm Corporation announced that it has reached an agreement in principle with the Securities and Exchange Commission (SEC) to resolve an investigation. The company first announced the investigation on September 30, 2013. The SEC Commissioners must still approve the agreement, which was made with the staff of the Enforcement Division of the Denver Regional Office, and thus the terms are not final. Brad Pyatt, the company’s Chief Executive Officer, in his individual capacity, has also reached an agreement `with the Denver Regional Office to resolve the investigation, which agreement is also subject to approval by the SEC Commissioners. The company is also aware that the SEC staff is considering the possibility of proposing that the SEC Commissioners approve charges against certain former officers, in their individual capacity, for violations of the federal securities laws. Under Nevada law, where the company is incorporated, the company may have future obligations to indemnify those individuals for expenses in connection with those investigations and to advance funds to the individuals for those expenses.

Muscle Pharm Corp. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Sale Guidance for the Year 2015

Muscle Pharm Corp. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net revenue of $32,672,000 against $37,493,000 a year ago. Loss from operations was $16,400,000 against $5,962,000 a year ago. Loss before provision for income taxes was $16,374,000 against $3,873,000 a year ago. Net loss was $16,236,000 or $1.39 per basic and diluted share against $3,988,000 or $0.45 per basic and diluted share a year ago. Adjusted LBITDA was $9,822,000 against $1,862,000 a year ago. For the year, the company reported net revenue of $177,389,000 against $110,878,000 a year ago. Loss from operations was $19,376,000 against $14,297,000 a year ago. Loss before provision for income taxes was $13,799,000 against $17,603,000 a year ago. Net loss was $13,832,000 or $1.25 per basic and diluted share against $17,718,000 or $2.46 per basic and diluted share a year ago. Adjusted EBITDA was $3,384,000 against $302,000 a year ago. For the year 2015, the company anticipates full-year 2015 net sales in the range of $210 to $220 million, with gross margin in the range of 31% to 33%.

Muscle Pharm Corp. to Report Q4, 2014 Results on Mar 16, 2015

Muscle Pharm Corp. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 16, 2015

Muscle Pharm Corp., Q4 2014 Earnings Call, Mar 17, 2015

Muscle Pharm Corp., Q4 2014 Earnings Call, Mar 17, 2015

MusclePharm Corporation Announces Executive Changes

MusclePharm Corporation announced the promotion of John Price to Chief Financial Officer. Price joined MusclePharm in July 2014, serving as the company's Executive Vice President of Finance, and as the Chairman of the company's Disclosure Committee and its Risk Management Officer. He will continue to be responsible for managing the company's risk assessment as it relates to financial reporting obligations, and oversight of a remediation plan. Price succeeds Donald Prosser, who will continue to be employed by MusclePharm as a non-executive officer through the remainder of his employment agreement, which terminates on April 15, 2015. His resignation was not due to any disagreement with the company on any matter relating to the operations, policies or practices. Prior to MusclePharm, Price served as Vice President of Finance-North America at Opera Software.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSLP:US $4.55 USD +0.02

MSLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natural Grocers by Vitamin Cottage Inc $26.55 USD +0.05
USANA Health Sciences Inc $117.90 USD -2.33
Vitamin Shoppe Inc $42.33 USD +0.42
View Industry Companies
 

Industry Analysis

MSLP

Industry Average

Valuation MSLP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MUSCLE PHARM CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.